New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 2, 2013
15:57 EDTKYTHKythera announces positive interim results from SMF study
KYTHERA Biopharmaceuticals announced positive interim results from a Phase IIIb, multi-center, open-label study (ATX-101-11-26) to evaluate the safety and efficacy of ATX-101, an investigational injectable drug for the reduction of unwanted submental fat, SMF, commonly known as double chin. The results, presented at the Late Breaking Research Symposium at the 71st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla., found that ATX-101 is well-tolerated and may be effective in reducing SMF by both clinician and patient reported outcome measures. The ATX-101 global clinical development program has enrolled more than 2,500 total patients, of which more than 1,500 have been treated with ATX-101.
News For KYTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 10, 2014
16:22 EDTKYTHKythera reports Q3 EPS (99c), consensus (88c)
Cash, cash equivalents and marketable securities totaled $117.4M at September 30, which compares to $63.7M, of which $9.7M was restricted, at September 30, 2013. The company had net use of cash, cash equivalents and marketable securities of $17.2M in Q3 and, based on current operating plans, believes its existing cash, cash equivalents and marketable securities will allow it to fund its operating plan through at least the next 12 months. Given anticipated activities for the remainder of the year, the company expects to end 2014 with a cash balance of $95M-$100M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use